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Aim: Controversy exists concerning the relation between Helicobacter pylori (HP) infection 
and coronary artery disease (CAD). We aimed to examine the relationship between HP infection 
and severity of coronary atherosclerosis in patients with chronic CAD.
Patients and methods: A total of 150 patients (109 [73%] men; mean age 62.61±10.23 years) 
scheduled for coronary artery bypass grafting surgery were consecutively enrolled in the 
cross-sectional study. According to rapid urease test and/or gastric biopsy samples stained 
with hematoxylin and eosin and according to Giemsa, patients were classified as HP positive 
(n=87; 58%) or HP negative (n=63; 42%). Coronary angiograms were scored by quantitative 
assessment, using multiple angiographic scoring system: 1) vessel score (number of coronary 
arteries stenosed $50%), 2) Gensini score (assigning a severity score to each coronary stenosis 
according to the degree of luminal narrowing and its topographic importance) and 3) angiographic 
severity score (number of coronary artery segments stenosed $50%).
Results: In comparison to HP-negative patients, HP-positive patients were more frequently 
hypertensive (P=0.014), had higher values of systolic (P=0.043) and diastolic (P=0.005) blood 
pressure and total cholesterol (P=0.013) and had lower values of high-density lipoprotein-
cholesterol (HDL-C; P=0.010). There were no significant differences between the groups in 
the severity of coronary atherosclerosis: vessel score (P=0.152), Gensini score (P=0.870) and 
angiographic severity score (P=0.734).
Conclusion: It is likely that HP infection is not a risk factor for the severity of coronary 
atherosclerosis in chronic CAD patients.
Keywords: atherosclerosis, coronary artery disease, Helicobacter pylori
Introduction
A hypothesis that a marked decline in the annual mortality from acute myocardial 
infarction (AMI), observed in the US since 1970s, might be associated with the 
reduction of duodenal peptic ulcer and improved Helicobacter pylori (HP) eradica-
tion, and the latest meta-analysis that confirmed the positive association between HP 
infection and an increased risk of AMI actualizes the theory about HP infection as a 
potential factor in the pathogenesis of coronary artery disease (CAD).1,2 Moreover, a 
recent report by Zuin et al3 suggested HP eradication as a measure in the primary and 
secondary CAD prevention.
Literature data concerning the relation of the HP infection with CAD are still 
controversial, reporting a strong positive association,4,6 a mild association7 and even 
negative findings.8–11 Results of the meta-analysis of the clinical studies suggest a 
closer relationship between the HP infection and the risk and outcomes of AMI and 
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acute coronary syndrome (ACS).2 At the same time, data 
regarding a link between HP infection and chronic CAD 
are inconsistent.4–13 Therefore, we aimed to test a correla-
tion between HP infection and the severity of coronary 
atherosclerosis in patients with chronic CAD. Assuming 
that HP infection represents an independent CAD risk factor, 
more severe coronary atherosclerosis was expected in HP-
positive patients.
Patients and methods
A total of 150 consecutive patients (109 [73%] men; mean 
age 62.61±10.23 years) who underwent coronary artery 
bypass grafting (CABG) surgery were enrolled in the cross-
sectional observational study. Patients with a history of HP 
eradication, immunological diseases, malignancies, ACS and 
percutaneous or surgical revascularization were excluded. 
The study was conducted according to the principles of 
the Declaration of Helsinki and was approved by the ethics 
committee of the University Hospital of Split. All participants 
gave their written informed consent.
Collection of data and CaD risk factors 
definition
Trained research assistants filled out the questionnaire on 
demographic characteristics (age, gender, height, weight), 
presence of coronary risk factors (smoking, diabetes, 
hypertension, hyperlipidemia, obesity) and use of medica-
tions with known impact on atherogenesis (beta-blockers 
[BBs], statins, angiotensin-converting enzyme inhibitors 
[ACE-Is], angiotensin receptor blockers [ARBs] and cal-
cium channel blockers [CCBs]). Coronary risk factors were 
defined as 1) diabetes mellitus: fasting blood glucose 
.6.9 mmol/L or a non-fasting glucose .11 mmol/L and/
or the use of antidiabetic medication; 2) hypertension: 
systolic blood pressure .140 mmHg, diastolic blood pres-
sure .90 mmHg or the use of antihypertensive drugs; 3) 
hyperlipidemia: total cholesterol (TC) .5.0 mmol/L, low-
density lipoprotein-cholesterol (LDL-C) .3.0 mmol/L, or the 
use of lipid-lowering therapy; 4) overweight: BMI (weight/
height2) .25 kg/m2 and 5) smoking: categorized as nonsmok-
ing or smoking (ie, current or stopped ,1 year ago).
esophagogastroduodenoscopy and hP 
testing
Esophagogastroduodenoscopy (EGDS; Olympus FB-25K; 
Olympus Corporation, Tokyo, Japan) was performed before 
the surgery in all patients, in order to probe for the presence 
of upper gastrointestinal lesions and determine the HP status. 
It was conducted under local anesthesia (Xylocain spray; 
Astra, Wedel, Germany) by two experienced endoscopists. 
Biopsy samples were obtained from the antrum and body of 
the stomach (two samples from each region), and HP was 
detected by staining with hematoxylin and eosin and accord-
ing to Giemsa. Additional two samples were obtained from 
the antrum for rapid urease test (CLOtest; Delta West Ltd., 
Perth, Australia). Patients were considered HP positive when 
either histology or the rapid urease test was positive.
Coronary angiography and determination 
of the extent and severity of coronary 
atherosclerosis
Angiographic scoring was performed according to three 
criteria: 1) vessel score: number of vessels with $50% steno-
sis of the lumen; 2) Gensini score: a severity score for each 
coronary artery stenosis, according to the degree of luminal 
narrowing and its topographic importance14 and 3) angio-
graphic severity score: number of coronary artery segments 
with a stenosis $50%, according to the American College 
of Cardiology/American Heart Association’s 16 segments 
model of the coronary tree.15
statistical analysis
Categorical data are presented as counts or proportions 
(percentages), and continuous data are presented as mean ± 
SD and median (25th–75th percentile). Data were tested 
for normal distribution using the Kolmogorov–Smirnov 
test. Continuous variables with normal distribution were 
compared by Student’s t-test and Mann–Whitney U-test if 
distribution was not normal. Differences between the cat-
egorical variables were tested using the chi-square test or 
Fisher’s exact test. Mean values were compared by analysis 
of variance (ANOVA) for normally distributed variables and 
Kruskal–Wallis test for non-normally distributed ones. All 
statistical analyses were two sided. Spearman’s correlation 
test was performed to test correlation between coronary 
risk factors and angiographic indicators of CAD severity. 
Statistical significance was presented with coefficient of cor-
relation (ρ) and the corresponding P-value. P-value ,0.05 
was considered as statistically significant. Statistical analyses 
were performed using the Statistical Package for the Social 
Sciences (SPSS) for Windows, version 19.0 (IBM Corpora-
tion, Armonk, NY, USA).
Results
Demographic and clinical variables of the included patients 
are presented in Table 1. HP positivity was observed in 
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87 (58%) patients. In comparison to HP-negative patients, 
HP-positive patients were more frequently hypertensive 
(P=0.014), had higher values of systolic (P=0.043) and 
diastolic (P=0.005) blood pressure and TC (P=0.013) and 
had lower values of high-density lipoprotein-cholesterol 
(HDL-C; P=0.010).
There were no differences between the groups in the use 
of medications with known impact on atherogenesis (BBs, 
statins, ACE-I/ARBs, CCBs; Table 1).
According to all performed methods of CAD scor-
ing, there were no differences in the severity of coronary 
atherosclerosis between the HP-positive and HP-negative 
patients (Table 2). Specifically, no significant differences 
were found between the groups in the vessel score (P=0.152), 
Gensini score (P=0.870) and angiographic severity score 
(P=0.734).
Spearman’s correlation test revealed a positive correla-
tion between age, systolic blood pressure, blood glucose, 
LDL-C and high-sensitivity C-reactive protein (hs-CRP) 
and values of the angiographic indicators of CAD severity 
scoring (Table 3).
Discussion
In the presented study, a lack of correlation between the HP 
infection and the severity of coronary atherosclerosis was 
detected in patients suffering from chronic CAD, despite 
the more unfavorable CAD risk profile observed in the HP 
group. Therefore, according to our results, it is unlikely that 
HP infection contributes to the pathogenesis of chronic CAD, 
even via detrimental effect on the classic CAD risk factors.
Although HP infection is the risk factor primarily for 
the development of gastric disorders (eg, chronic gastri-
tis, peptic ulcers, gastric adenocarcinoma), its potential 
association with a variety of extragastric diseases has been 
investigated.16–19 Since Mendall et al20 found serologic evi-
dence of a correlation between HP seropositivity and CAD, 
HP infection has been postulated to play a potential role in 
Table 1 Clinical and demographic characteristics of CaD patients 
with and without hP infection
HP+,  
n=87 (58%)
HP-,  
n=63 (42%)
P-value
age (years) 62.51±10.33 62.74±10.18 0.894
Men 66 (61) 43 (39) 0.397
BMi (kg/m2) 27.8±3.6 27.7±3.9 0.734
Cigarette smoking 27 (31) 16 (25) 0.568
hypertension 75 (86) 43 (68) 0.014
hypercholesterolemia 63 (72) 36 (57) 0.076
Diabetes mellitus 30 (34) 14 (22) 0.148
systolic blood pressure (mmhg) 129±16.12 125±15.1 0.043
Diastolic blood pressure (mmhg) 78.8±11.48 73.9±9.93 0.005
Blood glucose (mmol/l) 6.51±2.19 6.54±2.42 0.779
TC (mmol/l) 5.14±1.77 4.47±1.20 0.013
hDl-C (mmol/l) 1.03±0.31 1.19±0.35 0.010
lDl-C (mmol/l) 3.12±1.37 2.75±1.03 0.062
Triglycerides (mmol/l) 1.80±0.99 1.62±0.54 0.920
hs-CRP (mg/l) 7.33±4.53 5.82±3.54 0.057
BBs 75 (86) 53 (84) 0.722
aCe-is/aRBs 45 (52) 35 (56) 0.765
statins 83 (95) 61 (97) 0.864
CCBs 31 (36) 20 (32) 0.748
Note: Results are expressed as n (%) or mean ± sD.
Abbreviations: aCe-i, angiotensin-converting enzyme inhibitor; aRB, angiotensin 
receptor blocker; BB, beta-blocker; CaD, coronary artery disease; CCB, calcium 
channel blocker; hDl-C, high-density lipoprotein-cholesterol; hP, Helicobacter 
pylori; hs-CRP, high-sensitivity C-reactive protein; lDl-C, low-density lipoprotein-
cholesterol; TC, total cholesterol.
Table 2 severity of CaD in patients with and without hP 
infection
HP+,  
n=87 (58%)
HP-,  
n=63 (42%)
P-value
Vessel score 2 (1–3) 2 (1–3) 0.152
gensini score 80 (27–116) 56 (30–97) 0.870
angiographic severity score 4 (2–6) 3 (2–5) 0.734
Note: Results are expressed as median (25th–75th percentile).
Abbreviations: CaD, coronary artery disease; hP, Helicobacter pylori.
Table 3 Correlation between coronary risk factors and severity 
of coronary atherosclerosis – spearman’s correlation test
Vessel 
score
Gensini 
score
Angiographic 
severity score
age (years) ρ 0.082 0.188 0.288
P 0.320 0.021 ,0.001
BMi (kg/m2) ρ 0.011 0.055 0.027
P 0.895 0.501 0.747
systolic blood  
pressure (mmhg)
ρ 0.136 0.080 0.224
P 0.001 0.333 ,0.001
Diastolic blood  
pressure (mmhg)
ρ 0.070 -0.020 0.016
P 0.395 0.808 0.843
Blood glucose (mmol/l) ρ 0.287 0.268 0.251
P ,0.001 0.001 0.002
TC (mmol/l) ρ -0.10 -0.153 -0.102
P 0.222 0.061 0.213
lDl-C (mmol/l) ρ 0.167 0.207 0.156
P 0.041 0.011 0.057
hDl-C (mmol/l) ρ -0.081 -0.077 -0.102
P 0.537 0.349 0.213
Triglycerides (mmol/l) ρ 0.038 -0.028 -0.016
P 0.644 0.731 0.843
hs-CRP (mg/l) ρ 0.133 0.197 0.181
P 0.106 0.016 0.026
Note: ρ, coefficient of correlation.
Abbreviations: hDl-C, high-density lipoprotein-cholesterol; hs-CRP, high-
sensitivity C-reactive protein; lDl-C, low-density lipoprotein-cholesterol; TC, total 
cholesterol.
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the etiology of CAD. However, contrary to the results of the 
clinical studies and a recent meta-analysis that suggested a 
closer relationship between the HP infection and the risk and 
outcomes of AMI and ACS,2 data about a link between HP 
infection and chronic CAD are inconsistent.4–13
Concordantly with our results, Ozdogru et al10 and Jia 
et al,11 using Gensini score, found no significant correlation 
between HP seropositivity (HP IgG titer) and angiographi-
cally evaluated severity of coronary atherosclerosis. Con-
trary, using the extent score, Niccoli et al6 demonstrated a 
correlation between cytotoxin-associated gene A (CagA) 
antibody titer and severity of coronary atherosclerosis. 
In addition, despite an equal prevalence of HP seropositiv-
ity in subjects with and without CAD, Tsai and Huang12 
observed somewhat higher tendency of HP positivity among 
the CAD patients with triple vessel disease than those with 
double and single vessel disease. Two more recent studies 
investigated a possible link between the HP infection and 
coronary atherosclerosis using the coronary artery calcifica-
tion score measured by computed tomography. While Park 
et al7 showed a positive association between the HP positivity 
and early coronary atherosclerosis, suggesting a possible role 
of HP infection in the initiation of atherogenesis, Laek et al13 
reported no association between these entities.
Different observations about the link between the HP 
infection and severity of coronary atherosclerosis are pos-
sibly due to differences in defining CAD, selection bias of 
controls, methods used for detection of HP and imaging 
methods and scoring systems used for estimating the CAD 
severity. Therefore, in order to reduce the impact of meth-
odological variety and potential drawbacks, in the presented 
study, we have investigated the relationship between histo-
logically proven HP infection and the severity of coronary 
atherosclerosis in patients with chronic CAD using multiple 
angiographic scoring system.
In relation to the association between the HP infection 
and CAD pathogenesis, some studies have previously dem-
onstrated a potential link between HP infection and certain 
CAD risk factors. Namely, it has been reported that HP 
infection affects the lipid profile, mainly through the decrease 
of the HDL-C values, and is associated with impaired insu-
lin secretion and arterial hypertension.11,21,22 In addition, 
HP might influence atherogenesis via stimulating chronic 
inflammation.23 Moreover, there are reports about altera-
tion of some clinical and biochemical parameters related to 
CAD that occurred after HP eradication, suggesting the HP 
eradication as a potentially useful method in the prevention 
of CAD, especially in the developing countries.24–26 In this 
regard, our results are similar to the study by Jia et al,11 in 
which a positive correlation between the HP positivity and 
severity of coronary atherosclerosis has not been observed, 
despite a positive association detected between the HP 
infection and decreased serum levels of HDL-C. In addi-
tion, similar to our observation, an association between the 
HP infection and arterial hypertension has been found in 
some previous studies; however, no causative link has yet 
been proposed between these entities.22,24 Using Spearman’s 
correlation test, we observed a positive correlation between 
age, systolic blood pressure, LDL-C and hs-CRP and angio-
graphic indicators of CAD severity. Interestingly, among the 
mentioned CAD risk factors, only systolic blood pressure has 
been significantly different (higher) in HP-positive patients. 
Importantly, despite an observed difference in blood pressure 
values between HP-positive and HP negative patients, the 
mean blood pressure levels were still below a therapeutic 
threshold in both groups. Additionally, all included patients 
have been treated according to the guidelines for treatment 
of stable CAD and no differences between the two groups 
were present pertaining to use of medications known to have 
an effect on atherogenesis.15 Therefore, according to our 
results and the results of the abovementioned studies, it is 
unlikely that the HP infection contributes to the pathogen-
esis of chronic CAD, even through the modifications of the 
traditional CAD risk factors.
Even though our study suggests that the HP infection 
is likely not an independent risk factor for the severity of 
coronary atherosclerosis in chronic CAD patients, our results 
do not exclude the possible association between HP infec-
tion and acute coronary events. Namely, despite being the 
standard for evaluation of the severity of CAD, coronary 
angiography does not enable full characterization of the 
detected atherosclerotic plaque in the coronary artery wall, 
its activity and rupture tendency. Although colonization of 
coronary atherosclerotic plaques with HP has been observed 
using polymerase chain reaction (PCR), it has been demon-
strated that the rate of HP-infected plaques is significantly 
lower than the HP positivity detected by serology or gastric 
mucosa biopsy and is dominantly associated with the vulner-
ability of atherosclerotic plaques.27–29
Therefore, taking into consideration the results presented 
here and the results of some previous studies and their meta-
analyses, it is likely that the HP infection in the atheroscle-
rotic naive young population, through inflammatory and 
immunologic mechanisms, may initiate development of the 
atherosclerotic lesion(s), while in patients with vulnerable 
atherosclerotic plaques, it may provoke the plaque rupture 
Therapeutics and Clinical Risk Management 2017:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
937
Helicobacter pylori and coronary artery disease
and onset of the ACS.2 Therefore, according to the current 
data, it seems that in the context of CAD prevention, the latter 
group of patients might benefit most from HP eradication.
limitations of the study
Potential limitation of the study is the lack of confirmation of 
CagA seropositivity. However, it is important that a number 
of previous studies did not find a strong relationship between 
CagA seropositivity and either CAD or its risk factors (blood 
pressure, lipid profile, homocysteine level, fibrinogen) after 
adjustment for confounding factors.30–32
Conclusion
Our results suggest that HP infection is likely not an indepen-
dent risk factor for the severity of coronary atherosclerosis 
in chronic CAD patients. It seems that in the multifactorial 
pathogenesis of stable chronic CAD, traditional risk factors 
surpass potential impact of HP infection.
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